Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Background The immunosuppressive desmoplastic stroma of pancreatic cancer represents a major hurdle to developing an effective immune response. Preclinical studies in pancreatic cancer have demonstrated promising anti-tumor activity with Bruton tyrosine kinase (BTK) inhibition combined with programm...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Al B Benson, Anirban Maitra, Milind Javle, Michael Overman, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMJ Publishing Group 2020-05-01
Serie:	Journal for ImmunoTherapy of Cancer
Accesso online:	https://jitc.bmj.com/content/8/1/e000587.full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!